Prescriber Scope of Practice for General Psychiatry in Florida

If you’re a psychiatrist or psychiatric nurse practitioner wondering whether you can prescribe stimulants and other controlled substances through telehealth—or you’re trying to figure out the rules for your state—you’re not alone. The regulations around telehealth prescribing have been in constant flux since 2020, and with the DEA’s temporary flexibilities extended through 2026, many providers still have questions about what’s legal, what’s coming, and how to stay compliant.

The short answer: Yes, psychiatrists can currently prescribe ADHD medications and other controlled substances via telehealth without an initial in-person visit, thanks to federal emergency extensions. But that answer comes with important caveats about state laws, upcoming DEA rule changes, and compliance requirements that vary significantly depending on where you practice.

Let’s break down exactly what you need to know.

The Current Federal Landscape: DEA Extensions Through 2026

As of January 2026, the DEA and HHS have extended COVID-era telehealth prescribing flexibilities for controlled substances through December 31, 2026. This is the fourth such extension, designed to prevent care disruptions while the DEA finalizes permanent telemedicine rules.

What this means practically:

You can prescribe Schedule II–V controlled substances (including Adderall, Ritalin, Vyvanse, and other ADHD medications) via telehealth to new patients without requiring an initial in-person examination, as long as:

• You conduct a legitimate medical evaluation via real-time, two-way audio-video telehealth
• The prescription is for a legitimate medical purpose in the usual course of professional practice
• You’re licensed in the state where the patient is located
• You have a DEA registration that covers that state

This temporary flexibility has been a lifeline for telepsychiatry, allowing providers to treat ADHD, anxiety disorders, and other conditions that often require controlled medications without the burden of mandatory in-person visits.

However, ‘temporary’ is the key word here. The DEA is working on permanent rules that will likely change how telehealth prescribing works—possibly as soon as late 2026.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: The DEA’s Proposed Permanent Rules

In January 2025, the DEA announced three proposed rules that signal where telehealth prescribing is headed:

1. Special Telemedicine Registration for Controlled Substances

The DEA is creating a Special Telemedicine Prescriber Registration that would allow certain providers to prescribe controlled substances to new patients via telehealth without an in-person exam.

For Schedule III–V substances, any qualified prescriber could apply. For Schedule II substances (including most ADHD medications), the DEA initially proposed limiting this registration to:

• Board-certified psychiatrists
• Hospice/palliative care physicians
• Physicians at long-term care facilities
• Pediatricians (for specific medications)

This is significant for psychiatry. If finalized, board-certified psychiatrists could obtain this special registration and continue prescribing stimulants for ADHD via telehealth indefinitely, without ever requiring an in-person visit. The registration would come with additional compliance requirements—likely including mandatory PDMP checks, platform registration requirements, and periodic reporting—but it would provide a clear legal pathway for tele-prescribing.

2. Buprenorphine Treatment Expansion

For addiction treatment, the DEA proposed allowing clinicians to initiate buprenorphine for opioid use disorder via telehealth (including audio-only) for up to 6 months before requiring an in-person evaluation. This recognizes telehealth’s role in expanding access to medication-assisted treatment.

For general psychiatrists who treat substance use disorders, this rule would formalize what many have been doing under the emergency flexibilities and eliminate uncertainty.

3. Platform Registration and National PDMP

Under the proposed rules, online telehealth platforms would be required to register with the DEA for the first time. This is a direct response to high-profile cases of overprescribing by some telehealth companies.

The DEA also plans to establish a national Prescription Drug Monitoring Program that would integrate state PDMP data, making it easier for providers to track controlled substance prescriptions across state lines.

Bottom line: Prepare for more administrative requirements, but also more regulatory clarity. The DEA is trying to balance access with accountability.

The Economics of Telehealth Prescribing: Why This Matters for Your Practice

Beyond compliance, there’s a practical question: Is telehealth economically viable for treating ADHD and other psychiatric conditions?

Here’s the reality most providers face when trying to build or expand a telehealth practice:

DIY marketing is expensive and uncertain. If you’re trying to acquire patients on your own through SEO, Google Ads, or directory listings, you’re looking at:

• $200–500+ per qualified patient when you factor in all costs: agency fees, ad spend, staff time to qualify leads, no-show rates, and months of testing
• 6–12 months of consistent SEO investment before meaningful patient flow
• $15–40+ per click for mental health keywords on Google Ads, with most clicks not converting to booked appointments
• Directory listing fees (Psychology Today, Zocdoc) that add up quickly, plus fierce competition with hundreds of other providers on the same page

For solo practitioners or small groups, this can mean $3,000–5,000+ per month in marketing spend with no guarantee of results.

Platform-based models eliminate that risk. Services like Klarity Health use a pay-per-appointment model where you only pay a standard listing fee when a pre-qualified patient books with you. No upfront marketing spend, no monthly subscriptions, no wasted ad budget on clicks that don’t convert.

You get:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• Full control over your schedule

Instead of gambling on marketing channels, you pay only when you see patients—guaranteed ROI versus uncertain results.

This is especially important for controlled substance prescribing, where regulatory compliance adds administrative overhead. Working with a platform that handles patient acquisition and provides compliance infrastructure means you can focus on clinical care rather than marketing and tech setup.

State-by-State Requirements: Where the Rules Get Complicated

Federal law sets the floor, but states can impose stricter requirements. And when it comes to telehealth prescribing of controlled substances, state laws vary significantly.

California: Telehealth-Friendly with Strong Compliance Requirements

California doesn’t impose additional restrictions on telehealth prescribing of controlled substances beyond federal law. A proper patient relationship can be established via video, and you can prescribe stimulants for ADHD without requiring an in-person visit.

Key California requirements:

• CURES PDMP: You must check California’s prescription monitoring database before prescribing any Schedule II–IV controlled substance to a new patient, and every 4 months for ongoing treatment
• 100% e-prescribing: Since January 2022, all prescriptions (including non-controlled) must be submitted electronically with rare exceptions
• Licensing: Out-of-state psychiatrists must obtain a California medical license (no special telehealth license exists). California joined the Interstate Medical Licensure Compact (IMLC) in 2022, which streamlines this process

For PMHNPs in California: The state is transitioning to full practice authority. Experienced NPs (3+ years in supervised settings) can now apply for independent practice status (Category 104), allowing them to prescribe controlled substances without physician oversight. This transition is phasing in through 2026.

Texas: Physician-Only Schedule II Prescribing

Texas explicitly allows telehealth for psychiatry without requiring an in-person visit or patient site presenter for mental health conditions. However, there’s a major restriction for nurse practitioners:

Texas NPs and PAs cannot prescribe Schedule II controlled substances outside of hospital or hospice settings. This means any outpatient ADHD patient who needs stimulants must be treated by a physician.

Key Texas requirements:

• Real-time audio-video required for prescribing via telehealth
• Texas PMP: Mandatory PDMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• Chronic pain restriction: Controlled substances cannot be prescribed via telehealth for chronic pain management without an in-person evaluation (less relevant for psychiatry, but important to know)
• IMLC member: Out-of-state physicians can obtain a Texas license through the compact

For PMHNPs in Texas: You’ll need a supervising physician arrangement for all practice, and the physician must write any Schedule II prescriptions. Many telehealth platforms pair NPs with MDs specifically to handle this.

Florida: Psychiatric Exception Allows Schedule II Prescribing

Florida has one of the most detailed telehealth laws in the country, including a unique out-of-state provider registration system.

The key rule: Florida prohibits prescribing Schedule II controlled substances via telehealth unless it’s for:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home resident care

This psychiatric exception is critical. You can prescribe Adderall or other stimulants for ADHD via telehealth because ADHD is a psychiatric condition. You cannot prescribe Schedule II medications for pain management or other non-psychiatric uses via telehealth.

Key Florida requirements:

• Out-of-state registration: Florida allows out-of-state providers to register as telehealth providers without obtaining a full Florida license, though the registration has limitations
• E-FORCSE PDMP: Must check Florida’s prescription monitoring database before prescribing any controlled substance to patients age 16+
• E-prescribing mandate: Controlled substances must be e-prescribed (since 2021)
• Documentation: Document the psychiatric indication for any Schedule II medication prescribed via telehealth

For PMHNPs in Florida: Psychiatric NPs must have a collaborative agreement with a supervising physician. Florida’s autonomous practice pathway (created in 2020) excluded psychiatric specialties, so supervision is still required.

New York: Full PDMP Checks Required

New York is generally telehealth-friendly and doesn’t require an in-person visit before prescribing controlled substances via telemedicine.

Key New York requirements:

• I-STOP mandatory PDMP checks: You must check New York’s prescription monitoring database before prescribing every Schedule II, III, or IV controlled substance—not just the first time, but every prescription
• 100% e-prescribing: All prescriptions (controlled and non-controlled) must be submitted electronically since 2016
• No IMLC: New York hasn’t joined the Interstate Medical Licensure Compact, so out-of-state physicians must go through the full NY licensing process

For PMHNPs in New York: Since 2022, experienced NPs with 3,600+ clinical hours can practice independently without a collaborative agreement, including prescribing controlled substances. New NPs below that threshold still need physician oversight.

Pennsylvania: No Special Telehealth Restrictions

Pennsylvania doesn’t have a comprehensive telehealth statute yet, but practice is governed by general medical board regulations. The state doesn’t prohibit telehealth prescribing of controlled substances—you just need to meet the standard of care.

Key Pennsylvania requirements:

• PDMP checks: Mandatory check before first opioid or benzodiazepine prescription and periodically for ongoing treatment
• E-prescribing: Required for Schedule II–V controlled substances since 2019
• IMLC member: Pennsylvania joined the compact in 2021, making it easier for out-of-state physicians to obtain licensure

For PMHNPs in Pennsylvania: NPs need a collaborative agreement with at least one physician (actually two for prescriptive authority). They can prescribe Schedule II for up to 30 days and Schedule III–IV for up to 90 days under physician collaboration.

Illinois: Full Practice for Experienced NPs

Illinois allows telehealth prescribing under the same standard of care as in-person practice, with no special restrictions on controlled substances.

Key Illinois requirements:

• PDMP checks: Mandatory before prescribing opioids and recommended for other controlled substances
• E-prescribing: Required for all controlled substances since January 2023
• IMLC member: Makes multi-state licensing easier for physicians

For PMHNPs in Illinois: Experienced NPs can obtain Full Practice Authority (FPA) after 4,000 hours of clinical experience and 250 hours of additional training. However, even with FPA, Illinois law requires NPs to have a physician consultation arrangement for prescribing benzodiazepines or Schedule II opioids, with a 30-day supply limit. The rules around Schedule II stimulants are somewhat ambiguous but may fall under similar limitations.

Key Compliance Points Every Provider Should Know

Regardless of your state, certain compliance requirements apply to telehealth prescribing of controlled substances:

1. Use Real-Time Video for Initial Evaluations

While audio-only telehealth has been permitted for some services (particularly buprenorphine for opioid use disorder), the safest practice for initiating controlled substance prescriptions—especially stimulants—is to use two-way audio-video technology.

This meets the highest standard of care and aligns with what regulators expect for establishing a legitimate patient relationship.

2. Check Your State’s PDMP Every Time

Nearly every state now mandates prescription monitoring program checks before prescribing controlled substances. Some require checks only for opioids and benzodiazepines, others for all controlled medications.

Don’t skip this step. PDMP violations are among the most common compliance issues that lead to board disciplinary actions.

3. Complete the 8-Hour MATE Training

As of June 2023, all DEA prescribers must complete a one-time 8-hour training on substance use disorder and pain management before DEA renewal. This was mandated by the Medication Access and Training Expansion (MATE) Act.

Board-certified addiction psychiatrists are exempt (their specialty credential counts), but all other psychiatrists and PMHNPs must complete this training.

4. Document Thoroughly

Document your telehealth evaluations as thoroughly as you would in-person visits:

• Chief complaint and history of present illness
• Psychiatric history and medication history
• Mental status examination findings
• Clinical reasoning for controlled substance prescription
• Discussion of risks, benefits, and alternatives
• Treatment plan and follow-up schedule

This documentation is your protection if a prescription is ever questioned by regulators, and it demonstrates you met the standard of care.

5. Obtain Multi-State Licenses and DEA Registrations as Needed

You must be licensed in every state where your patients are located during telehealth visits. Telemedicine legally occurs where the patient is, not where you are.

You also need a DEA registration that covers each state. Many telehealth prescribers maintain multiple state licenses and DEA numbers—it’s a paperwork burden, but it’s required.

The IMLC (Interstate Medical Licensure Compact) has made this easier for physicians in member states. If you’re practicing in or expanding to California, Texas, Pennsylvania, or Illinois (all IMLC members), the compact can streamline obtaining additional state licenses.

What About Psychiatric NPs? Understanding Scope of Practice Differences

If you’re a psychiatric mental health nurse practitioner (PMHNP), your prescribing authority depends heavily on which state you’re in.

Full Practice States (like New York after 3,600 hours, California transitioning to full practice, Illinois with FPA) allow you to practice and prescribe independently, including controlled substances.

Reduced Practice States (like Pennsylvania) require a collaborative agreement with a physician but still allow you to prescribe controlled substances under that agreement.

Restricted Practice States (like Texas and Florida) require physician supervision and may significantly limit what you can prescribe—particularly Schedule II medications.

For telehealth platforms: This means NP recruitment and utilization strategies need to be state-specific. An experienced PMHNP in California might work completely independently by 2026, while a Texas PMHNP will always need a collaborating physician for Schedule II prescriptions.

Comparison: Directory Listings vs. Telehealth Platforms for Patient Acquisition

For ADHD and controlled substance prescribing specifically, working with a platform that understands the regulatory landscape and provides pre-qualified patients can eliminate the marketing uncertainty while you focus on clinical care.

FAQ: Common Questions About Telehealth Prescribing

Can I prescribe Adderall on the first telehealth visit?

Yes, under current federal flexibilities (extended through 2026), you can prescribe Schedule II stimulants like Adderall on an initial telehealth visit without a prior in-person examination, as long as you conduct a proper evaluation via audio-video and you’re licensed in the patient’s state.

However, always check your state law—some states may have additional requirements or restrictions.

Do I need to see ADHD patients in person eventually?

Not currently under federal law. Once the DEA’s permanent rules are finalized (likely in 2026), the requirement may change. The proposed rules include a special registration pathway for psychiatrists to continue prescribing Schedule II via telehealth indefinitely, but this hasn’t been finalized yet.

Best practice: For long-term controlled substance management, consider at least occasional in-person evaluations or coordination with a local provider for physical health monitoring, even if not legally required.

What happens when the DEA extension expires at the end of 2026?

The DEA is expected to finalize permanent telemedicine rules before the extension expires. These rules will likely include:

• A special telemedicine registration process for prescribing Schedule II medications (psychiatrists would be eligible)
• A 6-month telehealth allowance for buprenorphine before requiring in-person
• Platform registration requirements
• Enhanced PDMP reporting

Stay updated through DEA announcements and professional organizations like the APA.

Can psychiatric NPs prescribe ADHD medications via telehealth?

It depends on the state. In full practice states like New York (for experienced NPs), yes. In restricted states like Texas, no—Schedule II prescriptions must come from a physician. In Florida, NPs can prescribe under physician supervision but must meet the psychiatric treatment exception for Schedule II telehealth prescribing.

How do I handle patients who move to a different state?

You must obtain licensure in the new state (and a DEA registration for that state) before continuing to prescribe controlled substances via telehealth to them. This is non-negotiable—telehealth occurs where the patient is located, and you need full licensing authority there.

Is audio-only telehealth acceptable for prescribing ADHD medications?

Generally no, except in specific circumstances. The DEA’s current flexibilities focus on audio-video telemedicine. Audio-only has been explicitly allowed for buprenorphine treatment, but for other controlled substances, standard of care and regulatory expectations strongly favor video evaluation, especially for initial prescriptions.

Some states (like California and New York) have permitted audio-only for mental health services for reimbursement purposes, but that doesn’t necessarily mean it meets the prescribing standard for controlled substances.

What if a patient doesn’t have access to video technology?

Work with them to find a solution—many can access video on a smartphone even if they don’t have a computer. In rare cases where video is truly unavailable and the clinical situation warrants it, document why audio-only was necessary and ensure you’re following your state’s specific telehealth rules. For ongoing patients already established on medication, audio-only may be acceptable for refills in some states.

The Bottom Line: Telehealth Prescribing Is Here to Stay

Despite the regulatory complexity, telehealth has fundamentally changed psychiatric care delivery—and controlled substance prescribing via telemedicine isn’t going away.

The DEA’s proposed rules signal a move toward permanent, structured telehealth pathways rather than emergency exceptions. For psychiatrists, the likely availability of a special telemedicine registration for Schedule II prescribing is good news: it recognizes the unique nature of psychiatric practice and the appropriateness of tele-managing conditions like ADHD.

What you should do now:

1. Ensure you’re compliant with current rules in every state where you practice—check PDMP requirements, e-prescribing mandates, and licensing
2. Document thoroughly to demonstrate you’re meeting the standard of care for telehealth evaluations
3. Stay informed about DEA rule developments—finalization is expected in 2026
4. Consider your patient acquisition strategy—whether you’re building a solo practice or joining a platform, understand the real economics of telehealth marketing versus pay-per-appointment models
5. Plan for the future regulatory landscape—if you’re a board-certified psychiatrist, anticipate being able to continue Schedule II telehealth prescribing under the new special registration system

Telehealth offers psychiatrists and PMHNPs the opportunity to expand access to care, reduce overhead, and build flexible practices. With the right compliance framework and patient acquisition approach, you can build a sustainable telehealth practice that serves patients who desperately need psychiatric care—including those with ADHD and other conditions requiring controlled medications.

If you’re looking for a way to access pre-qualified patients without the marketing gamble, platforms like Klarity Health offer a clear path: no upfront costs, no monthly subscriptions, just pay when you see patients. It’s the economic model that makes telehealth psychiatry work—especially when combined with proper regulatory compliance and quality clinical care.

References

1. U.S. Department of Health and Human Services. (January 2, 2026). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. (January 16, 2025). DEA Announces Three New Telemedicine Rules to Continue Open Access While Establishing New Patient Protections. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Akerman LLP. (March 2023). Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

4. Substance Abuse and Mental Health Services Administration. (Updated 2023). The Elimination of the DATA Waiver (X-Waiver). https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

5. Tebra (The Intake). (December 4, 2025). Nurse Practitioner Scope of Practice Laws by State: 2025 Guide. https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices